Sinocelltech Group Limited (SHSE: 688520)
Health Care · Biotechnology · CN
CN¥37.05
+3.64% today · -34.3% 1Y
Sinocelltech Group Limited (SHSE: 688520) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.60B and employs 2,200 people.
Over the last twelve months the share price has lost 34.3%, trading between 31.35 and 57.60.
Tweenvest scores Sinocelltech Group Limited across four factors: quality 31/100, value 61/100, growth 100/100. Its strongest factor is growth.
688520 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.60B
- Revenue (TTM)
- $183.65M
- P/E
- —
- EPS
- -1.87
- Dividend yield
- —
- Beta (5Y)
- 0.71
- 52-week high
- CN¥57.60
- 52-week low
- CN¥31.35
- Avg volume (3M)
- —
- Shares outstanding
- 470.34M
- Employees
- 2,200
- Next earnings
- —
About Sinocelltech Group Limited
Sinocelltech Group Limited is a Beijing-based biotechnology enterprise. The company's primary focus lies in pioneering and refining the technologies required for both the creation and large-scale production of vital biological agents, specifically recombinant proteins, monoclonal antibodies, and vaccines, throughout China.
- ISIN
- CNE100003ZL3
- Founded
- 2007
- Listed since
- Jun 22, 2020
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Zai Lab LimitedNasdaqGM: ZLAB | $2.73B | $24.81 | +1.97% |
| Yili Chuanning Biotechnology Co.,Ltd.SZSE: 301301 | $2.73B | CN¥8.19 | +2.12% |
| BioArctic AB (publ)OM: BIOA B | $2.70B | Skr305.20 | -2.55% |
| BGI Genomics Co., Ltd.SZSE: 300676 | $2.62B | CN¥45.86 | +1.64% |
| Zealand Pharma A/SCPSE: ZEAL | $2.54B | Dkr237.00 | -4.97% |
| Bavarian Nordic A/SCPSE: BAVA | $2.53B | Dkr230.00 | +3.05% |
| Disc Medicine, Inc.NasdaqGM: IRON | $2.48B | $60.77 | -5.80% |
| Beam Therapeutics Inc.NasdaqGS: BEAM | $2.48B | $24.60 | -0.69% |
Figures last refreshed Oct 4, 2026.